Related Experiment Video

Updated: Jun 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

[Targeted cytotoxic drugs emerging for cancer therapy]

Teemu T Junttila1, Minna Tanner, Jorma Isola

  • 1Roche-Genentech Inc. South San Francisco, California, USA.

Duodecim; Laaketieteellinen Aikakauskirja
|March 30, 2011
PubMed

Insights

First-generation antibody drugs target cancer cells, while second-generation antibody-drug conjugates deliver cytotoxic agents directly. Trastuzumab-DM1 exemplifies this advancement, offering targeted cancer therapy.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Context:

  • Antibody drugs represent a significant advancement in cancer treatment.
  • First-generation antibodies target cancer cells externally.
  • Second-generation antibody-drug conjugates (ADCs) deliver cytotoxic payloads intracellularly.

Purpose:

  • To differentiate between first and second-generation antibody drugs.
  • To highlight the mechanism of action for antibody-drug conjugates.
  • To discuss the clinical development of trastuzumab-DM1 for breast cancer.

Summary:

  • First-generation antibody drugs identify cancer cells, inhibit growth signaling, and stimulate immune responses.
  • Second-generation antibody drugs, such as trastuzumab-DM1, are antibody-drug conjugates that transport cytotoxic agents into cancer cells for activation.
  • Trastuzumab-DM1 is a pioneering ADC in clinical trials for breast cancer, demonstrating targeted drug delivery.

Impact:

  • Antibody-drug conjugates offer a more targeted approach to cancer therapy.
  • The development of ADCs like trastuzumab-DM1 signifies progress in personalized cancer medicine.
  • Targeted cytotoxic drugs are expanding treatment options for various cancers.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...